A5071427769- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Ear and Head Tumors
- Head and Neck Surgical Oncology
- Prostate Cancer Treatment and Research
- Ferroptosis and cancer prognosis
- Immune Cell Function and Interaction
- Renal cell carcinoma treatment
- Lung Cancer Research Studies
- Radiopharmaceutical Chemistry and Applications
- Colorectal and Anal Carcinomas
- Pancreatic and Hepatic Oncology Research
- Cancer and Skin Lesions
- Inflammatory Biomarkers in Disease Prognosis
- Brain Metastases and Treatment
- COVID-19 and healthcare impacts
- Skin and Cellular Biology Research
- Glioma Diagnosis and Treatment
- COVID-19 and Mental Health
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Urticaria and Related Conditions
Massachusetts General Hospital
2024-2025
Harvard University
2024-2025
University of New Haven
2023
Yale University
2022-2023
Yale Cancer Center
2023
Albert Einstein College of Medicine
2020
Montefiore Medical Center
2020
Stony Brook University
2016
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and small-molecule radiopharmaceuticals targeting PSMA rapidly detect the location extent of disease. Here we evaluated preclinically 4 novel (99m)Tc-labeled inhibitors with potential for clinical translation molecular imaging cancer humans.Four derived from glutamate-urea-glutamate or glutamate-urea-lysine pharmacophores conjugated to CIM TIM chelators were radiolabeled (99m)Tc vitro vivo.High-affinity,...
PURPOSE Immune checkpoint inhibitors (ICIs) are now first-line therapy for most patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), cetuximab is often used as subsequent therapy. However, data describing efficacy in the post-ICI setting limited. METHODS We performed a single-institution retrospective analysis of R/M HNSCC treated cetuximab, either monotherapy or combination chemotherapy, after receiving an ICI. extracted objective response rate (ORR),...
Abstract Background Differentiated high‐grade thyroid carcinoma (DHGTC) is recently recognized by the World Health Organization (WHO) as a subgroup of carcinomas with features while retaining architectural and/or cytologic well‐differentiated follicular–cell‐derived tumors. The cytomorphology DHGTC not well documented despite potential implications for patient triage and management. Methods pathology archives six institutions were searched cases diagnosed on resection “high‐grade carcinoma”...
Abstract Background Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is an aggressive cancer with a median overall survival of only 12 months. Existing biomarkers have limited ability to predict treatment response or survival, exposing many patients the potential toxicity without certain clinical benefit. Circulating tumor DNA (ctDNA) has emerged as non-invasive, real-time biomarker that could address these challenges. Methods We analyzed 137 plasma samples from 16 R/M...
Immune checkpoint blockade (ICB) is the standard of care for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), yet efficacy remains low. The combined positive score (CPS) PD-L1 only biomarker approved to predict response ICB has limited performance. Tertiary Lymphoid Structures (TLS) have shown promising potential predicting ICB. However, their exact composition, size, spatial biology in HNSCC remain understudied. To elucidate impact TLS ICB, we utilized pre-ICB tumor...
Background Adenoid cystic carcinoma (ACC) is a rare, but lethal cancer with low response rates to systemic therapies, such as cytotoxic chemotherapy and immune-checkpoint inhibitors (ICIs). Despite extensive clinical trials, no effective treatments for patients recurrent or metastatic ACC are available, mortality remain poor. Methods We employed automated multiplex immunofluorescence (mIF), single-cell RNA sequencing (scRNA-seq) Gene Expression analysis, in-situ hybridization, spatial...
Abstract Background: Adenoid cystic carcinoma (ACC), a rare and lethal cancer, has shown low response rates to systemic therapies, such as cytotoxic chemotherapy, tyrosine kinase inhibitors immune-checkpoint (ICIs). Despite numerous clinical trials, no effective treatments for patients with recurrent or metastatic ACC have emerged, mortality remain stagnant. Therefore, we aimed characterize the immune landscape understand poor ICIs. Experimental Design: We leveraged automated multiplex...
Abstract Purpose: The incidence of human papillomavirus (HPV)–associated head and neck squamous cell carcinoma (HPV + HNSCC) is increasing in the United States. Currently, there are no early detection approaches for HPV HNSCC. Two blood-based analytes diagnosis HNSCC, circulating tumor DNA (ctHPVDNA) protein antibodies Ab), show promise, yet current lack adequate diagnostic accuracy broad clinical utility. Further, performance metrics across various assays detecting these alone or...
6083 Background: Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 5.3% of cancer-related mortality worldwide, with an estimated 660,000 new diagnoses 325,000 deaths annually. Curative-intent surgery or definitive chemoradiotherapy remain the only two curative treatment modalities patients HNSCC but recurrence rates vary from 10-50% survival is still limited some emphasizing need accurate predictive prognostic models. This study developed validated AI model that...
e18115 Background: Over half of patients with locally advanced, HPV-independent head and neck squamous cell carcinoma (HNSCC) experience recurrence. The detection minimal residual disease (MRD) early recurrence have the potential to significantly improve patient outcomes. However, current surveillance methods poor sensitivity diagnostic accuracy. Circulating tumor DNA (ctDNA)-based MRD may predict recurrence-free survival (RFS) overall (OS) in several cancers, such as colorectal lung cancer,...
2658 Background: Treatment of severe irAEs with multiple immunosuppressive therapies (ISTs) decreases the morbidity and mortality these conditions. Nevertheless, rates risk factors for infectious complications in this population are not known. Methods: We conducted a retrospective study patients (pts) who received an immune checkpoint inhibitor (ICI) experienced ≥1 irAE requiring treatment corticosteroids along at least two lines steroid-sparing ISTs administered either concurrently or...
While great strides have been made in the treatment of advanced renal cell carcinoma (RCC) with emergence immune checkpoint inhibitors (ICIs) and VEGFR-targeting drugs, sizable proportions patients still do not respond to upfront therapy long-term responses only occur a minority patients. There is therefore need for development better predictors response an increased understanding mechanisms resistance these therapies. Alternative checkpoints outside PD-1/PD-L1 axis, such as LAG3, implicated...
Background The tumor microenvironment (TME) contributes to cancer progression and treatment response therapy, including in renal cell carcinoma (RCC). Prior profiling studies, single-cell transcriptomics, often involve limited sample sizes lack spatial orientation. TME of RCC brain metastases, a major cause morbidity, also remains largely uncharacterized. Methods We performed digital on the NanoString GeoMx platform using 52 validated immuno-oncology markers tissue microarrays representing...
Immune checkpoint inhibitors (ICIs) are increasingly being used to manage multiple tumor types. Unfortunately, immune-related adverse events affect up 60% of recipients, often leading treatment discontinuation in settings where few alternative cancer therapies may be available. Checkpoint inhibitor induced colitis (ICI-colitis) is a common toxicity for which the underlying mechanisms poorly defined. To better understand changing colon-specific and peripheral immune environments over course...
e18021 Background: Immune checkpoint blockade (ICB) is the standard of care for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), yetefficacy remains low. Current assessment tumor response relies on a single proportional biomarker expressed in immune cells (Combined Positive Score, CPS) without differentiation by type, potentially explaining its limited predictive value. Tertiary Lymphoid Structures (TLS) have shown stronger association with improved ICB than PD-L1....
Montefiore Medical Center (MMC) is a large tertiary care center in the Bronx, New York City, with 245 internal medicine residents. Beginning on February 29, 2020, residents became ill COVID-19-like illness (CLI), which required absence from work. There was initially shortage of personal protective equipment and delays SARS-CoV-2 testing, gradually improved during March April 2020.We evaluated relationship between CLI-related work rates MMC's COVID-19 hospital census over time.Data resident...
Abstract Background: Immune checkpoint inhibition is an increasingly popular strategy for the management of numerous malignancies. Unfortunately, severe inflammatory toxicities affect up to 60% patients, often leading treatment discontinuation in settings where few alternative therapies are available control disease. Checkpoint inhibitor induced colitis a common toxicity which underlying mechanisms poorly defined. Methods: To better understand changing colon-specific and peripheral immune...
e14609 Background: ICI rechallenge after irAE has become a significant clinical dilemma, with recurrence rates of 30-40% rechallenge. Here we examine factors influencing across 10-year period at the Massachusetts General Hospital (MGH), where Severe Immunotherapy Complications service is available to provide multidisciplinary expertise. Methods: We included patients admitted MGH for an from August 2011 July 2023. collected baseline demographics, regimens, and features. The choice used was...